Abstract
Antibody technology has advanced a long way since the early days of Kohler and Milstein's antibody-secreting murine hybridomas1; and although Kohler and Milstein's invention was not patented, patent protection for the new generation of murine, chimeric, humanized and human antibody-based drugs is essential to safeguard their future development.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Webber, P. M. Protecting your inventions: the patent system. Nature Rev. Drug Discov. 2, 823–830 (2003).
Noelle v. Lederman 355 F.3d 1343, 1349 (US Fed. Cir. 2004)
Webber, P. M. Patent primer: patenting microorganisms. Nature Rev. Drug Discov. 5, 13 (2006).
DakoCytomation Denmark A/S. Dako as monoclonal antibodies against human protein Mcm3, process for their production, and their use. Patent EP 1165615 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webber, P. Patenting antibodies. Nat Rev Drug Discov 5, 97 (2006). https://doi.org/10.1038/nrd1963
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd1963
